Prostate Cancer

Prostate cancer develops when cells in the prostate gland begin to grow abnormally and multiply in an uncontrolled manner. The prostate is a small gland located below the bladder and in front of the rectum. It surrounds part of the urethra and contributes fluid to semen.

Prostate cancer is one of the most common cancers affecting men. However, it is not a single type of disease with the same behaviour in every patient. Some prostate cancers grow slowly and may remain confined to the prostate for many years, while others are more aggressive and can spread beyond the prostate to nearby lymph nodes, bones or other organs.

This difference in behaviour is one of the most important aspects of prostate cancer care. A diagnosis does not automatically mean that immediate surgery or chemotherapy is required. Treatment decisions depend on the cancer’s grade, stage, PSA level, imaging findings, biopsy results, overall health and the patient’s priorities.

At [Hospital/Clinic Name], prostate cancer care begins with establishing an accurate diagnosis and determining how extensive the disease is. Treatment may include active surveillance, surgery, radiation therapy, hormone-based treatment, chemotherapy, targeted therapies or combinations of these approaches.

What Is the Prostate?

The prostate is part of the male reproductive system. It sits just below the bladder and surrounds the urethra, the tube through which urine leaves the body.

The prostate normally grows with age. Benign enlargement of the prostate, known as benign prostatic hyperplasia (BPH), is common in older men and is not cancer.

Symptoms such as frequent urination, a weak urinary stream or difficulty starting urination are often caused by BPH or other non-cancerous conditions rather than prostate cancer.

Early prostate cancer may not cause any urinary symptoms at all. This is why evaluation of an abnormal PSA level or other risk factors can be important even when a man feels well.

Risk Factors for Prostate Cancer

The risk of prostate cancer increases with age. A family history of prostate cancer can also increase risk, particularly when close relatives were diagnosed at a younger age.

Inherited genetic changes can contribute to prostate cancer risk in some families. Certain genetic mutations, including changes involving BRCA1 and BRCA2, may be associated with a higher risk and can influence treatment decisions in advanced disease.

Ethnicity and family history may also influence an individual’s risk profile.

Having a risk factor does not mean that a person will develop prostate cancer, and men without obvious risk factors can still develop the disease.

Men concerned about their risk should discuss an appropriate screening and evaluation strategy with a qualified healthcare professional.

Symptoms of Prostate Cancer

Early prostate cancer often produces no specific symptoms.

When symptoms occur, they may include:

• Difficulty starting urination
• Weak or interrupted urinary flow
• Increased frequency of urination
• Urgency to urinate
• Waking frequently at night to urinate
• Blood in the urine or semen
• Difficulty maintaining an erection
• Pain associated with ejaculation

These symptoms are not specific to cancer and are commonly caused by benign prostate enlargement, urinary infections or other urological conditions.

More advanced prostate cancer can cause persistent bone pain, unexplained weight loss, fatigue or other symptoms related to spread of the disease.

Any persistent or unexplained urinary or reproductive symptom should be evaluated rather than assumed to be cancer or dismissed as a normal part of ageing.

PSA Testing

The prostate-specific antigen (PSA) blood test is an important tool in the assessment of prostate cancer.

PSA is produced by prostate tissue, and an elevated PSA level can occur for several reasons. Prostate cancer is one possibility, but benign prostate enlargement, prostatitis, urinary infection, recent procedures and other factors can also increase PSA.

Therefore, an elevated PSA does not by itself diagnose prostate cancer.

Doctors may consider the PSA level alongside age, prostate size, previous PSA measurements, family history, physical examination and imaging findings.

A rising PSA or a persistently abnormal result may require further investigation.

Digital Rectal Examination

A digital rectal examination (DRE) allows a doctor to assess the prostate through the rectum.

The examination can provide information about prostate size, symmetry and areas that feel unusually firm or irregular.

A normal examination does not rule out prostate cancer, and an abnormal examination does not necessarily mean cancer is present. It is one part of the overall assessment.

MRI and Prostate Biopsy

When prostate cancer is suspected, multiparametric magnetic resonance imaging (MRI) can provide detailed information about the prostate and help identify areas that may be suspicious for clinically significant cancer.

MRI findings can help guide decisions about whether a biopsy is appropriate and, when biopsy is required, help target suspicious areas.

A prostate biopsy involves taking small tissue samples from the prostate for examination by a pathologist.

The biopsy provides information about whether cancer is present and, if so, how aggressive the cancer appears to be.

The pathology report may include a Gleason score or Grade Group, which helps classify the cancer’s biological behaviour.

Understanding Prostate Cancer Grade and Stage

Two concepts are particularly important after diagnosis: grade and stage.

Grade describes how abnormal the cancer cells look under the microscope and provides information about how aggressively the cancer may behave.

Stage describes how far the cancer has spread.

A cancer confined to the prostate is considered localised. If it has extended just beyond the prostate or into nearby structures, it may be locally advanced. If it has spread to distant lymph nodes, bones or other organs, it is considered metastatic.

Modern prostate cancer assessment may combine PSA, biopsy findings, MRI and other imaging to determine the extent of disease.

For higher-risk or suspected advanced cancers, additional imaging may be recommended to look for disease outside the prostate.

Active Surveillance

Not every prostate cancer needs immediate treatment.

Men with certain low-risk and selected favourable intermediate-risk cancers may be offered active surveillance.

Active surveillance is not the same as ignoring the cancer. It involves structured monitoring using PSA tests, clinical assessment, repeat imaging and, when appropriate, repeat biopsy.

The purpose is to avoid or delay treatment-related side effects when the cancer is unlikely to cause harm in the near term, while maintaining the opportunity to treat the disease if evidence of progression appears.

If surveillance findings indicate that the cancer is becoming more aggressive, definitive treatment can then be considered.

Radical Prostatectomy

Radical prostatectomy is a surgical treatment in which the prostate gland and seminal vesicles are removed.

It is primarily used for selected men with prostate cancer that has not spread to distant organs.

The operation can be performed through different surgical approaches, including open surgery, laparoscopic surgery or robotic-assisted surgery.

Where cancer control and anatomy permit, surgeons may consider nerve-sparing techniques to preserve the nerves involved in erectile function.

However, nerve preservation is not always possible or appropriate. If the cancer is close to or involves the relevant nerves, removing them may be necessary to achieve adequate cancer control.

Urinary and Sexual Function After Prostate Surgery

Urinary continence and erectile function are important considerations before radical prostatectomy.

Temporary urinary leakage can occur after surgery as the urinary control mechanism recovers. Many men experience improvement over time, although the degree and speed of recovery vary.

Erectile dysfunction is also a recognised possible consequence of prostate surgery because the nerves and blood vessels involved in erection are located close to the prostate.

Recovery of erectile function depends on factors such as age, erectile function before surgery, cancer characteristics and whether the nerves could safely be preserved.

Treatment options for postoperative erectile dysfunction can include oral medicines, vacuum devices, injection therapy and, in selected patients, penile prosthesis surgery.

Radiation Therapy

Radiation therapy can be used as a primary treatment for localised or locally advanced prostate cancer and may also be used in other stages of disease.

External beam radiation therapy delivers carefully planned radiation to the prostate and surrounding target areas.

Brachytherapy is another approach in which radioactive sources are placed within or close to the prostate, depending on the cancer’s characteristics and the treatment plan.

Radiation may also be combined with hormone therapy for certain higher-risk cancers.

Potential side effects can include urinary symptoms, bowel changes and effects on erectile function. The likelihood and severity depend on the treatment plan and individual patient factors.

Hormone Therapy

Prostate cancer cells often depend on male hormones, particularly testosterone, for growth.

Androgen deprivation therapy (ADT) reduces the effect or production of these hormones and is an important treatment for advanced prostate cancer. It may also be combined with radiation therapy in selected patients with higher-risk localised or locally advanced disease.

Additional medicines that more directly inhibit androgen signalling may be used in certain advanced cancers.

Hormonal treatment can cause side effects including hot flushes, reduced sexual desire, erectile dysfunction, changes in body composition, fatigue, bone-density loss and metabolic changes.

Because prostate cancer treatment can be long term, these effects need to be monitored and managed as part of ongoing care.

Treatment for Advanced and Metastatic Prostate Cancer

When prostate cancer has spread beyond the prostate, treatment generally focuses on controlling the disease, reducing symptoms, slowing progression and maintaining quality of life.

Treatment may involve hormone therapy combined with other systemic treatments such as chemotherapy, androgen-receptor pathway inhibitors or selected radiopharmaceutical treatments.

When prostate cancer spreads to the bones, patients may experience pain or an increased risk of fractures. Bone health and the risk of skeletal complications therefore form an important part of advanced prostate cancer management.

The exact treatment depends on previous therapies, cancer biology, extent of spread, symptoms and the patient’s overall health.

Genetic Testing in Prostate Cancer

Genetic testing can be relevant for selected men with prostate cancer, particularly those with advanced disease or a strong family history of prostate, breast, ovarian or pancreatic cancers.

Identifying an inherited genetic mutation may have implications for treatment and may also provide information that could be relevant to family members.

Tumour testing may also be considered in certain advanced cancers to identify molecular characteristics that could influence treatment selection.

Genetic counselling may be appropriate when inherited cancer risk is suspected.

Follow-Up After Prostate Cancer Treatment

Prostate cancer requires long-term monitoring.

After radical prostatectomy, PSA should fall to a very low or undetectable level because most PSA-producing prostate tissue has been removed. A subsequent rise in PSA may require further evaluation.

For men treated with radiation, PSA behaves differently and may decline gradually. Follow-up is therefore interpreted according to the type of treatment received.

Patients undergoing active surveillance require regular PSA testing and other assessments to identify signs of progression.

Follow-up also provides an opportunity to address urinary, sexual, hormonal, emotional and general health concerns after treatment.

A Personalised Approach to Prostate Cancer

There is no single treatment that is right for every man with prostate cancer.

A younger man with a small, low-risk cancer may reasonably choose active surveillance, while another patient with higher-risk localised disease may benefit from surgery or radiation. Someone with metastatic disease requires a different treatment strategy altogether.

The decision should take into account cancer control, potential side effects, life expectancy, other medical conditions and the patient’s personal priorities.

At [Hospital/Clinic Name], prostate cancer care focuses on accurate diagnosis, appropriate staging and a clear discussion of treatment options. Where appropriate, urologists work alongside medical oncologists, radiation oncologists, radiologists and pathologists to develop an integrated treatment plan.

Take the Next Step

An abnormal PSA result does not automatically mean that you have prostate cancer, but it should be evaluated appropriately.

If you have an elevated or rising PSA, an abnormal prostate examination, a strong family history or other concerns about prostate cancer, a specialist consultation can help determine whether further testing is necessary.

If prostate cancer has already been diagnosed, understanding the cancer’s grade and stage is the foundation for choosing the right treatment.

At [Hospital/Clinic Name], patients receive individualised prostate cancer evaluation and management, from diagnosis and staging through active surveillance, surgery, radiation, systemic treatment and long-term follow-up.